- Home
- CTRM vs LGVN Comparison
CTRM vs LGVN Comparison
Compare CTRM & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRM
- LGVN
- Stock Information
- Founded
- CTRM 2016
- LGVN 2014
- Country
- CTRM Cyprus
- LGVN United States
- Employees
- CTRM N/A
- LGVN N/A
- Industry
- CTRM Marine Transportation
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- CTRM Consumer Discretionary
- LGVN Health Care
- Exchange
- CTRM Nasdaq
- LGVN Nasdaq
- Market Cap
- CTRM 23.1M
- LGVN 23.4M
- IPO Year
- CTRM N/A
- LGVN 2021
- Fundamental
- Price
- CTRM $2.31
- LGVN $1.67
- Analyst Decision
- CTRM
- LGVN Strong Buy
- Analyst Count
- CTRM 0
- LGVN 3
- Target Price
- CTRM N/A
- LGVN $8.67
- AVG Volume (30 Days)
- CTRM 35.8K
- LGVN 827.1K
- Earning Date
- CTRM 08-07-2025
- LGVN 08-13-2025
- Dividend Yield
- CTRM N/A
- LGVN N/A
- EPS Growth
- CTRM N/A
- LGVN N/A
- EPS
- CTRM 0.38
- LGVN N/A
- Revenue
- CTRM $66,243,379.00
- LGVN $2,225,000.00
- Revenue This Year
- CTRM N/A
- LGVN N/A
- Revenue Next Year
- CTRM N/A
- LGVN $51.48
- P/E Ratio
- CTRM $6.12
- LGVN N/A
- Revenue Growth
- CTRM N/A
- LGVN 127.50
- 52 Week Low
- CTRM $1.98
- LGVN $1.14
- 52 Week High
- CTRM $5.49
- LGVN $4.29
- Technical
- Relative Strength Index (RSI)
- CTRM 49.12
- LGVN 63.06
- Support Level
- CTRM $2.25
- LGVN $1.43
- Resistance Level
- CTRM $2.44
- LGVN $1.80
- Average True Range (ATR)
- CTRM 0.08
- LGVN 0.15
- MACD
- CTRM 0.00
- LGVN 0.02
- Stochastic Oscillator
- CTRM 50.00
- LGVN 72.92
About CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.